Bioquell Regulatory News (BQE)

BIOQUELL PLC

Intention to return approximately £42.7 million toBioquell shareholders by way of a tender offer

Anticipated tender offer terms: £2 per Share in respect of50% of the issued Share capital

The Board of Bioquell PLC ("Bioquell" or the "Company") announces that it has concluded that it would be helpful for the Strategic Review process and in the best interests of Bioquell shareholders ("Shareholders") if a substantial proportion of the cash currently on the Company's balance sheet were returned to Shareholders by way of tender offer.

Accordingly, the Board of Bioquell announces that it intends to launch in due course and subject to Shareholder approval, a tender offer in respect of 50% of the Company's issued ordinary Share capital at a price of £2.00 per Share.

The Company currently has approximately 42.7 million Shares in issue.

A detailed announcement, and the documentation required to effect this return of capital, will follow as soon as practical.

The Company remains in an offer period under the framework provided by a formal sales process under the Takeover Code

Commenting on the announcement, Nigel Keen, Chairman of Bioquell PLC said:

"It has become clear from our discussions that having such a large amount of cash on our balance sheet is unhelpful within the context of the Strategic Review and accordingly we have concluded that we should proceed with returning the equivalent of a £1 per Share in cash to Bioquell shareholders via a tender offer."

- Ends -

ENQUIRIES

Bioquell PLC - tel: 01264 835 900

Nigel Keen

Nick Adams

Michael Roller

N+1 Singer - tel: 020 7496 3000

Nic Hellyer

James White